The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression

This study investigated the possible association of the MAOA T941G gene variant with differential antidepressant response to mirtazapine and/or paroxetine in 102 patients with major depression (DSM‐IV criteria) participating in a randomized double‐blind controlled clinical trial. Female mirtazapine‐...

Full description

Saved in:
Bibliographic Details
Published in:American journal of medical genetics. Part B, Neuropsychiatric genetics Neuropsychiatric genetics, 2007-04, Vol.144B (3), p.325-331
Main Authors: Tadić, André, Müller, Matthias J., Rujescu, Dan, Kohnen, Ralf, Stassen, Hans H., Dahmen, Norbert, Szegedi, Armin
Format: Article
Language:English
Subjects:
Adult
Adult and adolescent clinical studies
Antidepressive Agents - therapeutic use
Biological and medical sciences
Depression
Depressive Disorder, Major - drug therapy
Depressive Disorder, Major - genetics
Double-Blind Method
Female
Gene Frequency
Genetic Linkage
Genotype
Humans
major depression
Male
MAOA polymorphism
Medical genetics
Medical sciences
Mianserin - analogs & derivatives
Mianserin - therapeutic use
Middle Aged
mirtazapine
Miscellaneous
Monoamine Oxidase - genetics
Mood disorders
paroxetine
Paroxetine - therapeutic use
Polymorphism, Single Nucleotide
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Sex Characteristics
Time Factors
Treatment Outcome
treatment response
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study investigated the possible association of the MAOA T941G gene variant with differential antidepressant response to mirtazapine and/or paroxetine in 102 patients with major depression (DSM‐IV criteria) participating in a randomized double‐blind controlled clinical trial. Female mirtazapine‐treated patients homozygous for the T‐allele had a significantly faster and better treatment response than TG/GG‐patients. In males, we failed to show an association between MAOA T941G gene variant and mirtazapine response. In the paroxetine‐treated group, there were no significant differences in treatment response between MAOA T941G genotype groups. Time course of response and antidepressant efficacy of mirtazapine, but not paroxetine, seem to be influenced in a clinically relevant manner by this allelic variation within the MAOA gene, at least in female patients. An independent replication of our finding is needed. If replicated, genotyping of this locus could become a promising tool to predict response to mirtazapine treatment in females suffering from major depression. © 2006 Wiley‐Liss, Inc.
ISSN:1552-4841
1552-485X
DOI:10.1002/ajmg.b.30462